Molnupiravir for SARS-CoV-2 infection: Public health and policy implications

J Infect. 2023 Feb;86(2):121-122. doi: 10.1016/j.jinf.2022.10.040. Epub 2022 Dec 23.
No abstract available

Publication types

  • Review

MeSH terms

  • Antiviral Agents
  • COVID-19*
  • Humans
  • Hydroxylamines
  • Public Health*
  • SARS-CoV-2

Substances

  • molnupiravir
  • Hydroxylamines
  • Antiviral Agents